Physician profile
Wan Li Yang
NPI 1720395825
$3,351.81
in general payments reported to CMS, 2019-2025
38 companies · $73.04 in 2025
The $73.04 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2022: $361 · 2023: $1,406 · 2024: $1,395 · 2025: $73.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,492 · Education: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,492.11 |
| Education | $382.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $223.53 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $219.72 | 2022-2023 | Imbruvica, Epkinly |
| Daiichi Sankyo INC. | $209.90 | 2022-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $195.57 | 2023-2024 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $175.82 | 2022-2024 | Xtandi, Padcev |
| Janssen Biotech, INC. | $173.80 | 2022-2024 | Darzalex, Imbruvica, Talvey |
| Novartis Pharmaceuticals Corporation | $161.86 | 2022-2024 | |
| Incyte Corporation | $149.41 | 2021-2023 | Jakafi |
| Seagen INC. | $141.14 | 2021-2023 | Padcev, Tukysa, Adcetris |
| Karyopharm Therapeutics INC. | $131.68 | 2022-2024 | Xpovio |
| Bayer Healthcare Pharmaceuticals INC. | $125.68 | 2022-2024 | |
| Abbvie INC. | $124.66 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $120.15 | 2022-2024 | Iclusig |
| Glaxosmithkline, LLC. | $107.73 | 2022-2024 | Ojjaara, Zejula, Jemperli |
| Genentech USA, INC. | $94.51 | 2021-2024 | Tecentriq, Alecensa, Rozlytrek |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $89.90 | 2023-2024 | Opdivo, Augtyro |
| Ipsen Biopharmaceuticals, INC | $84.21 | 2021-2024 | Onivyde |
| Celgene Corporation | $75.68 | 2023-2024 | Reblozyl, Opdualag, Pomalyst |
| Sobi, INC | $74.99 | 2024 | |
| Coherus Oncology, INC. | $73.37 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $71.42 | 2023-2024 | Lynparza, Enhertu |
| Puma Biotechnology, INC. | $58.56 | 2023-2024 | Nerlynx |
| Stemline Therapeutics INC. | $49.00 | 2023-2024 | Orserdu |
| Gilead Sciences, INC. | $46.83 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $42.87 | 2022-2024 | Libtayo |
| Mirati Therapeutics, INC. | $41.02 | 2023-2024 | Krazati |
| Lilly USA, LLC | $35.62 | 2023 | Verzenio, Jaypirca |
| Beigene USA, INC. | $34.28 | 2022-2024 | Tevimbra |
| Servier Pharmaceuticals LLC | $33.54 | 2024 | |
| Jazz Pharmaceuticals INC. | $31.45 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.50 | 2024 | Relistor |
| Aveo Pharmaceuticals, INC. | $24.12 | 2024 | |
| Eisai INC. | $22.33 | 2024 | |
| Amgen INC. | $17.06 | 2023 | Lumakras |
| Deciphera Pharmaceuticals INC. | $16.49 | 2023 | Qinlock |
| Myriad Genetic Laboratories, INC. | $15.09 | 2024 | Myrisk |
| Array Biopharma INC | $14.87 | 2024 | Mektovi, Braftovi, Tukysa |
| Legend Biotech USA INC. | $13.45 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wan Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.